Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment

The absence of potent therapeutic option accounts for the dismal prognosis of advanced hepatocellular carcinoma (HCC) with high mortality and recurrence rate. For a decade, sorafenib is the only approved systemic drug in the first-line setting and warrants as the standard-of-care for HCC in the adva...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transl Gastroenterol Hepatol
Autori principali: Siu, Elaine Hon-Lam, Chan, Anthony Wing-Hung, Chong, Charing Ching-Ning, Chan, Stephen Lam, Lo, Kwok-Wai, Cheung, Siu Tim
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2018
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286919/
https://ncbi.nlm.nih.gov/pubmed/30603725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2018.10.16
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi